• 作者：Clara M¨¦ndez Perles ; Clara Sang¨¹esa G¨®mez ; M¨®nica Fern¨¢ndez-Castro ; Jos¨¦ Luis Andreu S¨¢nchez
• 关键词：Sí ; ndrome de Sjö ; gren ; Sistema nervioso central ; Sistema nervioso perifé ; rico
• 刊名：Seminarios de la Fundaci¨®n Espa?ola de Reumatolog¨ªa
• 出版年：2013
• 出版时间：July-September, 2013
• 年：2013
• 卷：14
• 期：3
• 页码：80-85
• 全文大小：575 K

Primary Sj?gren syndrome (PSS) is an autoimmune disease characterized by lymphocytic infiltration in exocrine glands, mainly the salivary and lachrymal glands, resulting in xerophthalmia and xerostomia. Occasionally, PSS has extra-glandular manifestations, including central (CNS) and peripheral nervous system (PNS) involvement. The reported prevalence varies in the literature, mainly because of heterogeneity in the diagnostic and classification criteria. Involvement of the PNS is more frequent than that of the CNS, presenting as axonal, sensory, autonomic or small fiber neuropathies and mononeuritis multiplex. CNS manifestations may be focal or diffuse and are associated with increased extra-glandular involvement and the presence of autoantibodies. Treatment is based on corticosteroids. In severe, refractory- or corticosteroid-dependant cases, immunosuppressant agents such as azathioprine or cyclophosphamide may be useful. Observational studies have suggested that rituximab is useful in some PSS extra-glandular manifestations. Currently, clinical trials with new biological agents such as belimumab and epratuzumab are being conducted in PSS.